| Immune responses and vaccinations | Lifetime | 2 | NL 2 | 99.83 |
| COVID-19 Impact on Reproduction | Lifetime | 5 | NL 2 | 99.78 |
| Inflammasome and immune disorders | Lifetime | 13 | NL 2 | 99.88 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 34 | NL 1 | 99.66 |
| Immune Response and Inflammation | Lifetime | 89 | NL 6 | 99.72 |
| Gout, Hyperuricemia, Uric Acid | Lifetime | 16 | NL 1 | 99.15 |
| Diabetes and associated disorders | Lifetime | 185 | NL 3 | 99.04 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 148 | NL 18 | 99.34 |
| Immune cells in cancer | Lifetime | 237 | NL 8 | 98.60 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 147 | NL 13 | 98.88 |
| Osteoarthritis Treatment and Mechanisms | Lifetime | 303 | NL 21 | 98.54 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 453 | NL 12 | 98.10 |
| Vaccine Coverage and Hesitancy | Lifetime | 377 | NL 9 | 97.42 |
| Cell Adhesion Molecules Research | Lifetime | 965 | NL 30 | 97.36 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 291 | NL 16 | 97.66 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 688 | NL 19 | 97.23 |
| IL-33, ST2, and ILC Pathways | Lifetime | 323 | NL 6 | 96.86 |
| Pharmacological Effects of Natural Compounds | Lifetime | 730 | NL 5 | 95.77 |
| Case Reports on Hematomas | Lifetime | 62 | NL 3 | 95.86 |
| Inflammatory mediators and NSAID effects | Lifetime | 746 | NL 13 | 96.16 |
| NF-κB Signaling Pathways | Lifetime | 450 | NL 2 | 96.03 |
| Antifungal resistance and susceptibility | Lifetime | 881 | NL 22 | 96.07 |
| Vector-borne infectious diseases | Lifetime | 960 | NL 14 | 95.18 |
| Fungal Infections and Studies | Lifetime | 958 | NL 23 | 94.63 |
| Phagocytosis and Immune Regulation | Lifetime | 609 | NL 22 | 92.20 |
| Inflammation biomarkers and pathways | Lifetime | 371 | NL 16 | 82.93 |
| Bartonella species infections research | Lifetime | 990 | NL 18 | 63.44 |
| Whipple's Disease and Interleukins | Lifetime | 640 | NL 15 | 61.14 |
| Immune responses and vaccinations | 2021-2025 | 2 | NL 2 | 99.65 |
| COVID-19 Impact on Reproduction | 2021-2025 | 15 | NL 2 | 98.89 |
| Inflammasome and immune disorders | 2021-2025 | 31 | NL 1 | 97.99 |
| Diabetes and associated disorders | 2021-2025 | 43 | NL 2 | 98.51 |
| Gout, Hyperuricemia, Uric Acid | 2021-2025 | 45 | NL 1 | 94.24 |
| Immune cells in cancer | 2021-2025 | 304 | NL 6 | 94.24 |
| Epigenetics and DNA Methylation | 2021-2025 | 672 | NL 19 | 92.21 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 415 | NL 17 | 90.38 |
| Immune Response and Inflammation | 2021-2025 | 336 | NL 11 | 86.30 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 337 | NL 12 | 87.02 |
| Case Reports on Hematomas | 2021-2025 | 30 | NL 1 | 86.98 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 590 | NL 13 | 80.23 |
| Vector-borne infectious diseases | 2021-2025 | 955 | NL 14 | 80.88 |
| HIV-related health complications and treatments | 2021-2025 | 952 | NL 23 | 75.93 |
| Dermatological diseases and infestations | 2021-2025 | 433 | NL 10 | 58.36 |
